FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230801215> ?p ?o ?g. }

• W4230801215 abstract "Abstract BackgroundThe use of pyronaridine-artesunate (PA) has been associated with scarce transaminitis in patients. This analysis aimed to evaluate the hepatic safety profile of repeated treatment with PA versus artemether-lumefantrine (AL) in patients with consecutive uncomplicated malaria episodes in Bobo-Dioulasso, Burkina Faso.MethodsWe secondarily analyzed data from a clinical trial conducted from 2012 to 2015, in which patients with uncomplicated malaria were assigned to either PA or AL arms and followed up to 42 days. Subsequent malaria episodes within a 2-years follow up period were also treated with the same ACT initially allocated. Transaminases (AST/ALT), alkaline phosphatase (ALP), total and direct bilirubin were measured at days 0 (baseline), 3, 7, 28 and on some unscheduled days if required. The proportions of non-clinical hepatic adverse events (AEs) following first and repeated treatments with PA and AL were compared within study arms. The association of these AEs with retreatment in each arm was also determined using a logistic regression models.ResultsA total of 1379 malaria episodes were included in the intention to treat analysis with 60% of all cases occurring in the AL arm. Overall, 179 non-clinical hepatic AEs were recorded in the AL arm versus 145 in the PA arm. Elevated ALT was noted in 3.05% of treated malaria episodes, elevated AST 3.34%, elevated ALP 1.81%, and elevated total and direct bilirubin with 7.90% and 7.40% respectively. Retreated participants were less likely to experience elevated ALT and AST than first episode treated participants in both arms. One case of Hy’s law condition was recorded in a first treated participant of the PA arm. Patients from the retreatment group were 76% and 84% less likely to have elevated ALT and AST respectively in the AL arm and 68% less likely to present elevated ALT in the PA arm. In contrast, they were almost 2 times more likely to experience elevated total bilirubin in both arms.ConclusionPyronaridine-artesunate and artemether-lumefantrine showed similar hepatic safety when used repeatedly in patients with uncomplicated malaria. Pyronaridine-artesunate represents therefore a suitable alternative to the current first line antimalarial drugs in use in endemic areas.Trial RegistrationPan African Clinical Trials Registry. PACTR201105000286876" @default.
• W4230801215 created "2022-05-11" @default.
• W4230801215 creator A5005371655 @default.
• W4230801215 creator A5018877466 @default.
• W4230801215 creator A5024467013 @default.
• W4230801215 creator A5028327649 @default.
• W4230801215 creator A5036633224 @default.
• W4230801215 creator A5037217462 @default.
• W4230801215 creator A5037647381 @default.
• W4230801215 creator A5044655448 @default.
• W4230801215 creator A5046985654 @default.
• W4230801215 creator A5053380158 @default.
• W4230801215 creator A5062398556 @default.
• W4230801215 creator A5068293536 @default.
• W4230801215 creator A5087440676 @default.
• W4230801215 creator A5087512882 @default.
• W4230801215 date "2020-08-27" @default.
• W4230801215 modified "2023-09-27" @default.
• W4230801215 title "Hepatic safety of repeated treatment with pyronaridine-artesunate (PA) versus artemether-lumefantrine (AL) in patients with uncomplicated malaria: A secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso" @default.
• W4230801215 doi "https://doi.org/10.21203/rs.3.rs-63636/v1" @default.
• W4230801215 hasPublicationYear "2020" @default.
• W4230801215 type Work @default.
• W4230801215 citedByCount "0" @default.
• W4230801215 crossrefType "posted-content" @default.
• W4230801215 hasAuthorship W4230801215A5005371655 @default.
• W4230801215 hasAuthorship W4230801215A5018877466 @default.
• W4230801215 hasAuthorship W4230801215A5024467013 @default.
• W4230801215 hasAuthorship W4230801215A5028327649 @default.
• W4230801215 hasAuthorship W4230801215A5036633224 @default.
• W4230801215 hasAuthorship W4230801215A5037217462 @default.
• W4230801215 hasAuthorship W4230801215A5037647381 @default.
• W4230801215 hasAuthorship W4230801215A5044655448 @default.
• W4230801215 hasAuthorship W4230801215A5046985654 @default.
• W4230801215 hasAuthorship W4230801215A5053380158 @default.
• W4230801215 hasAuthorship W4230801215A5062398556 @default.
• W4230801215 hasAuthorship W4230801215A5068293536 @default.
• W4230801215 hasAuthorship W4230801215A5087440676 @default.
• W4230801215 hasAuthorship W4230801215A5087512882 @default.
• W4230801215 hasBestOaLocation W42308012151 @default.
• W4230801215 hasConcept C126322002 @default.
• W4230801215 hasConcept C141071460 @default.
• W4230801215 hasConcept C197934379 @default.
• W4230801215 hasConcept C203014093 @default.
• W4230801215 hasConcept C2776120307 @default.
• W4230801215 hasConcept C2777513400 @default.
• W4230801215 hasConcept C2778048844 @default.
• W4230801215 hasConcept C2778059366 @default.
• W4230801215 hasConcept C2778371730 @default.
• W4230801215 hasConcept C2778629330 @default.
• W4230801215 hasConcept C44249647 @default.
• W4230801215 hasConcept C71924100 @default.
• W4230801215 hasConcept C90924648 @default.
• W4230801215 hasConceptScore W4230801215C126322002 @default.
• W4230801215 hasConceptScore W4230801215C141071460 @default.
• W4230801215 hasConceptScore W4230801215C197934379 @default.
• W4230801215 hasConceptScore W4230801215C203014093 @default.
• W4230801215 hasConceptScore W4230801215C2776120307 @default.
• W4230801215 hasConceptScore W4230801215C2777513400 @default.
• W4230801215 hasConceptScore W4230801215C2778048844 @default.
• W4230801215 hasConceptScore W4230801215C2778059366 @default.
• W4230801215 hasConceptScore W4230801215C2778371730 @default.
• W4230801215 hasConceptScore W4230801215C2778629330 @default.
• W4230801215 hasConceptScore W4230801215C44249647 @default.
• W4230801215 hasConceptScore W4230801215C71924100 @default.
• W4230801215 hasConceptScore W4230801215C90924648 @default.
• W4230801215 hasLocation W42308012151 @default.
• W4230801215 hasLocation W42308012152 @default.
• W4230801215 hasOpenAccess W4230801215 @default.
• W4230801215 hasPrimaryLocation W42308012151 @default.
• W4230801215 hasRelatedWork W139547829 @default.
• W4230801215 hasRelatedWork W1494735451 @default.
• W4230801215 hasRelatedWork W2006887406 @default.
• W4230801215 hasRelatedWork W2021293206 @default.
• W4230801215 hasRelatedWork W2101046223 @default.
• W4230801215 hasRelatedWork W2147717453 @default.
• W4230801215 hasRelatedWork W2156524292 @default.
• W4230801215 hasRelatedWork W2777069987 @default.
• W4230801215 hasRelatedWork W3114240435 @default.
• W4230801215 hasRelatedWork W3145823580 @default.
• W4230801215 isParatext "false" @default.
• W4230801215 isRetracted "false" @default.
• W4230801215 workType "article" @default.